DHA, RvD1, RvD5, and MaR1 reduce human coronary arteries contractions induced by PGE2

Prostaglandins Other Lipid Mediat. 2023 Apr:165:106700. doi: 10.1016/j.prostaglandins.2022.106700. Epub 2022 Dec 15.


In patients with coronary artery disease (CAD), plasma levels of pro-inflammatory lipid mediators such as PGE2 and TxA2 are increased. They could increase vascular contraction while EPA and DHA could reduce it. Studies have been mostly conducted on animal vessels. Therefore, the aim of the study was to investigate if EPA, DHA, and DHA-derived metabolites: RvD1, RvD5 and MaR1 can modulate contraction of human coronary arteries (HCA) induced by PGE2 or TxA2 stable analogue (U46619). DHA and EPA relaxed HCA pre-contracted with PGE2. 18 h-incubation with DHA but not EPA reduced the PGE2-induced contractions. Pre-incubation with RvD1, RvD5 and MaR1 reduced the PGE2-induced contractions. Indomethacin did not significantly modify the PGE2 responses. L-NOARG (inhibitor of nitric oxide synthase), reduced only the PGE2-induced contractions in RvD1-treated rings. Finally, FPR2/ALX, GPR32 and LGR6 receptors are detected in HCA by immunofluorescence. Our results indicate that DHA and its metabolites could be beneficial for HCA blood flow and could be a therapeutic perspective for patients with CAD.

Keywords: Human coronary arteries; Mar1; RvD1; RvD5; SPM; Vascular tone.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Animals
  • Coronary Vessels*
  • Dinoprostone* / pharmacology
  • Docosahexaenoic Acids / metabolism
  • Docosahexaenoic Acids / pharmacology
  • Eicosapentaenoic Acid
  • Humans
  • Thromboxane A2


  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Dinoprostone
  • Docosahexaenoic Acids
  • Thromboxane A2
  • Eicosapentaenoic Acid